Last reviewed · How we verify
recurrent unresectable or metastatic NPC
Approved treatments
- Loqtorzi · Coherus Biosciences Inc
Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- recurrent unresectable or metastatic NPC patent landscape — cliff calendar, originator estates, attackable patents
- recurrent unresectable or metastatic NPC treatment landscape brief
- recurrent unresectable or metastatic NPC treatment updates RSS
Frequently asked questions about recurrent unresectable or metastatic NPC
What drugs treat recurrent unresectable or metastatic NPC?
Tracked treatments include Loqtorzi.
What is the treatment for recurrent unresectable or metastatic NPC?
Standard treatment for recurrent unresectable or metastatic NPC includes Loqtorzi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: recurrent unresectable or metastatic NPC patent cliff · recurrent unresectable or metastatic NPC CI report
- Treatment: Loqtorzi · Coherus Biosciences Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing